Fig. 6: Engineered hMSCs are compatible with hydrogel scaffold treatment for wound healing. | Nature Communications

Fig. 6: Engineered hMSCs are compatible with hydrogel scaffold treatment for wound healing.

From: Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice

Fig. 6

a VEGFA MSCs were delivered by injection in the wound bed or by HyStem®-HP hydrogel embedding on top of the wound bed on the day of wounding. b Box and whiskers plot shows AUC of individual wounds, which were normalized against mean AUCs of PBS controls (biological replicates: n = 10 per treatment group). Minima and maxima are bounded by whiskers, lower bounds, centers, and upper bound of boxes represent the 25th, 50th, and 75th percentiles, respectively. Mean AUCs of all treatment and control groups were different according to ordinary one-way ANOVA test (p < 0.0001). Plotted treatment groups have no significant differences in AUCs. c Wound images show appearances of wounds treated with HyStem®-HP hydrogel alone (label: “Hydrogel”) and embedded VEGFA MSCs (label: “Hydrogel:VEGFA MSCs”) over the course of observation period. Masson’s trichrome stained cross-section images show structure of granulation tissues at the end of observation period. Cyan boxes indicate location of high-resolution images. Cyan arrowheads indicate residual Hystem®-HP hydrogel. Source data are available in the Source data file.

Back to article page